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1. Introduction 
1.1 Pain classification 
Pain is nowadays one of the major reasons for medical consultation worldwide. Pain is 
always a subjective experience, which is often verbally non-communicable. Sometimes it 
starts as acute pain arising from a disease (such as cancer), an injury (such as a road 
accident), or a post-surgical intervention; then it persists and becomes a disease itself (1-3). 
The International Association for the Study of Pain (IASP) definition of pain is accordingly 
the following: “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” (1). Many people, however, 
report pain also in absence of tissue damage or any likely pathophysiological cause; usually 
this is due to psychological factors. For this reason pain has two components: a perceptive 
component, nociception, sensorial reception of the potential harmful stimulus to the central 
nervous system, and experiential component, individual, which is the psychological 
perception of an unpleasant sensation.  
In relationship to the duration of painful perception, pain can be acute, or chronic. Acute 
pain has a short duration, and usually has a clear cause/effect, and disappear when the 
damage is repaired. Chronic pain is defined as pain persisting for more than 3 months, it has 
no prevention treatments, persists for several months or years and often does not have a 
single or identifiable cause.  
As concerning the pathological classification of pain, there are different types of chronic 
pain, according to the tissues involved. Neuropathic pain, for example, is defined by IASP 
as “Pain caused by a lesion or disease of the somatosensory nervous system”, and can be 
central, if “Pain is caused by a lesion or disease of the central somatosensory nervous 
system” or peripheral if “Pain caused by a lesion or disease of the peripheral somatosensory 
nervous system”, including visceral organs (1). Trigeminal neuralgia, and postherpetic 
neuralgia are examples of neuropathic pain.  
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Nociceptive pain, on the contrary, is defined by IASP as “Pain that arises from actual or 
threatened damage to non-neural tissue and is due to the activation of nociceptors”, which 
are high-threshold sensory receptor of the peripheral somatosensory nervous system that is 
capable of transducing and encoding noxious stimuli (1). This type of pain can be somatic or 
visceral, according to the localizartion of tissues involved; it usually indicates a damage 
occurred in non-neural tissues, hence in presence of a normally functioning somatosensory 
nervous system to contrast with the abnormal function seen in neuropathic pain. 
The two types of pain may also coexist in the same patient, in this case pain can be identified 
as mixed neuropatic and nociceptive. 
1.2 Cancer pain 
Pain may also be secondary to cancer, in this case is defined as cancer pain. Chronic cancer 
pain represents the third largest health problem in the world, and involves around 30% of 
the world’s population (4). The World Health Organization (WHO) has stated that 
inadequate treatment of cancer pain represents a serious problem for public health all over 
the world (5). It is calculated that there are 10 million new cases of cancer and 6 million 
deaths from this illness worldwide. It is estimated that the incidence of cancer, currently 
greater in developed countries, will become more significant in developing countries as a 
result of the better prevention strategies being adopted in the former. The WHO program on 
the control of cancer has estimated that by the year 2020, around 70% of the 20 million new 
cases of tumours will be in the developing world, where most patients are diagnosed when 
the disease is already in the last stages.  
More than 50% of cancer patients do not undergo adequate pain treatment (6). The pain 
prevents patients from carrying out normal daily activities and influences appetite, mood, 
self-esteem, relationships with others and mobility. In some countries it is seen that 
untreated pain leads to a desire for death, euthanasia or assisted suicide (4). Pain relief 
improves the quality of life (7). 
Unfortunately, cancer pain is often not treated or is treated inadequately. The WHO have 
demonstrated that most, if not all, cases of cancer pain, could be treated successfully, if existing 
medical knowledge and suitable therapies were put into practice. There exists a lacuna in the 
treatment that is represented by the difference between what could be done and what is 
actually done in the fight against cancer pain. Training, informing health workers and 
facilitating access to analgesic treatments and palliative care can close this gap (5). 
The WHO Expert Committee on Cancer Pain Relief and Active Supportive Care (8), stated in 
1990 that "freedom from pain should be considered a right of every cancer patient and 
access to pain therapy as a measure of respect for this right". 
In 1986, the World Health Organization, in an effort to optimize cancer pain therapy, 
suggested a simple three point analgesic ladder (figure 1) for the use of opioids for the 
treatment of cancer pain (6).  
Although adoption of the therapies suggested by this analgesic ladder improves pain 
management in the majority of patients, it is estimated that from 5% to 15% of patients with 
cancer pain are unable to adequately control their pain, following these guidelines (9-11). In 
addition there are pains classified as "breakthrough pains" (12) which are difficult to manage 
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and contain, both because they are unpredictable and because there is a lack of suitable 
drugs. In order to tackle this need, new drug formulations have been developed such as 
immediate release morphine, transmucosal fentanyl (13) and indications for invasive 
treatments with analgesic infusion in the liquor. 
 
Fig. 1. The World Health Organization analgesic ladder for treating cancer pain 
 
Fig. 2. Adaptation of the WHO ladder 
Therefore, in 1997, the WHO, according to the model described by Catala, proposed a 
change in the analgesic ladder, adding a fourth step dedicated to intrathecal (IT) drug 
administration (14, 15) (figure 2). They suggested that intrathecal therapy is indicated in 
patients who are unable to control painful symptoms with traditional method of 
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administration or in those who cannot tolerate high doses of oral opioids because of 
systemic side-effects. 
However, while this practice has been known for a while (16-18), it has still not yet become 
sufficiently widespread as to define its role. When it should be used, for what pain types it is 
most effective and what effect it has on the biological homeostasis of the patient (18) and the 
development of their primary pathology. 
2. Intrathecal administration 
2.1 History of infusion pumps  
Intratecal (IT) delivery systems for opioid infusion have been introduced in the later 1980s 
for the treatment of chronic pain, because of their several advantages: opioid-related 
systemic effects are reduced, lower opioid dosages are required, and opioid receptors are 
directly reached (19).  
The first models of spinal analgesia were experimented in rats by Yaksh and Rudy in 1976 
(19). They used morphine administered via a chronically inserted catheter, and observed 
that opioids elevated the analgesic threshold when the infusion was performed into the 
subarachnoid space. This effect was antagonized by naloxone, and had onset and duration 
variable according to the type of opioid used. Fentanyl onset was 2-3 minutes and expired in 
20-30 minutes, whereas morphine required twice as long to start its effect, but it lasted 
longer, up to 2 hours.  
IT therapy is a key therapeutic option for patients who have failed all other treatment 
avenues, require high enteral or parenteral dosages, or have unbearable opioid related-side 
effects (20). 
The study of the spinal pathways in patients with non-malignant pain is still being 
developed, as there are many obstacles which prevent its widespread application. Anyway 
the long-term intrathecal administration with totally implantable systems has been 
recommended for the treatment of noncancer pain, both by a consensus of specialists from 
the United States in 1997 (21) and by the International Consensus Conference in Brussels in 
1998 (22). Experts believe that it should be used in pathologies characterized by the presence 
of long-term persistent pain, where other therapeutic strategies have been judged to be 
ineffective or inapplicable because of serious adverse effects (23). 
2.2 IT drugs 
There are five main classes of IT drugs: opioids, including morphine, hydromorphone, 
sufentanil, fentanyl, methadone, and ,meperidine; local anaestetics, such as bupivacaine, 
ropivacaine, and tetracaine; adrenergic agonist: clonidine and tiazinidine; N-methyl-D-
aspartate (NMDA) antagonist, including dextrorphan, dextromethorphan, mematine and 
ketamine; other agents, such as baclophen, ziconotide, midazolam, neostigminie, aspirin, 
and droperidol (24). 
Opioids are a heterogeneous group of synthetic and semisynthetic opium derivates, their 
analgesic effect and therapeutic use is lost in time. The power of an opioid depends on 
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several factors: affinity with their receptor, specific pharmacological potency, or the ability 
to express the desired effect. The amount and type of receptors in a tissue affects the 
response to opioids in terms of both quality and quantity (intensity and duration of effect). 
Intratecal infusion of major opioids is increasingly used for the treatment of chronic pain, 
and morphine is the gold standard (25). Morphine delivered IT, and its metabolites, 
especially morphine-6-glicuronide (M-6-G) (26), can provide prolonged analgesic because 
there is a slow replacement of the cerebrospinal fluid (CSF) over time, and it is 
approximately ten time more potent than the same amount administered systemically or 
epidurally (27-29). In the chronic infusion, M-6-G plays a larger role; it enters the CSF from 
the plasma, but can also be created in situ by the brain (30-32). 
Hydromorphone administered intratecally has been less applied, and few studies are 
present in the literature. It is known to be 5 times more potent than morphine, but the 
adverse events profile is equivalent or better than that of morphine (33). 
Bupivacaine belongs to the amino amide group; it is known to act synergistically with the 
opioids for the treatment of pain (34-36) allowing the administration of lower doses of 
morphine to achieve the same analgesic effect (37). The use of IT bupivacaine has been 
shown to be free of bone marrow toxicity and to have positive synergy with opioids (35, 36). 
Despite the excellent results obtained with morphine and bupivacaine, there still remains 
difficulty in treating all pains, particularly the pains of neuropathic origin. 
Clonidine has been shown to be helpful in difficult to treat cases. It has been reported that 
the spinal administration of clonidine not only acts synergistically when administered with 
opioids, increasing the analgesic power and reducing side-effects (38), but it is also a 
powerful analgesic agent when used alone, especially for the treatment of neuropathic pain 
(39-41). 
Local anesthetics and opioids work on differing analgesic systems, so low doses of these 
agents, when added to each other IT, provide analgesic synergy (42). Moreover, the use of a 
low dose of bupivacaine when added to IT morphine allows for a low dose of morphine 
thereby reducing the incidence of opioid-related side-effects (43). Although morphine is the 
gold standard agent used for IT therapy, experts in the field of IT therapy today use a 
variety of drug combinations, such as morphine/bupivacaine, hydromorphone, and 
morphine/clonidine (32, 44). 
An interdisciplinary expert panel of both physicians and non-physicians in the field of 
intrathecal therapies met in 2007 at the Polyanalgesic Consensus Conference, in order to 
update previous recommendations/guidelines for the management of pain by IDDS (45). 
They suggested the following classification and drug dosages (table.1). 
Morphine and ziconotide are approved by the Food and Drug Administration of the United 
States for intrathecal analgesic use and are recommended for first line therapy for 
nociceptive, mixed, and neuropathic pain. Hydromorphone is recommended based on 
clinical widespread usage and apparent safety. Fentanyl is a line 2 agent and is 
reccommended by the consensus conference when the use of the more hydrophilic agents of 
line 1 (morphine, ziconotide) result in intractable supraspinal side effects (table 2).  
www.intechopen.com
 
Topics in Neuromodulation Treatment 
 
116 
 
Table 1. IT drug doses as recommended by the polyanalgesic consensus 2007. 
 
Table 2. Recommended algorithm for intrathecal polyanalgesic therapies, 2007. 
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Combinations of opioid/ziconotide or opioid/bupivacaine or clonidine are recommended 
for mixed and neuropathic pain and may be used interchangeably. Clonidine alone or in 
combination with opioids such as morphine/ hydromorphone /fentanyl; bupivacaine 
and/or clonidine mixed with ziconotide are line 3 agents, and may be used when agents in 
line 2 fail to provide analgesia or side effects occur when these agents are used. Sufentanil 
alone or mixed with bupivacaine and/or clonidine plus ziconotide (suggested for 
neuropathic pain) is recommended in line 4. Midazolam and octreotide are line 5, and 
should be tried when all other agents in lines 1–4 have failed in end-of-life patients. 
Experimental agents are line 6, and must only be used experimentally and with appropriate 
Independent Review Board (IRB) approved protocols (45). 
IT drug administration can be performed through bolus or continuos infusion. Bolus 
administration may result in better distribution of anesthetic solution compared with 
continuous infusion of the same anesthetic solution. Automated methods of bolus injection, 
moreover, may combine the advantages of manual boluses and continuous infusion, while 
sparing on drug consumption.  
The constant infusion, however, is the most diffused method of IT drug administration, and 
the comparison between bolus and constant-flow pumps shows no difference as concerning 
efficacy and safety in non-cancer pain (46, 47) and cancer pain (48). 
2.3 Opioid receptor 
Opioid action is mediated by the activation of opioid receptors. The receptors are several and 
the major are called μ, k and , are responsible for both the positive effects (analgesia), but also 
of opioid related side effects (respiratory depression, itching, vomiting etc.) (table 3). 
 
Table 3. Major Opioid receptors 
The opioid receptor is a macromolecule that includes an extracellular N-terminus, 7 
transmembrane helical twists, 3 extracellular and intracellular loops, and an intracellular C-
terminus (49) (Fig. 3). Once the receptor is activated, it releases the inhibitory G protein, 
which diffuses within the membrane and activates a cascade of biochemical reactions 
leading to the decrease of cAMP intracellular. The final result is the neuronal inhibition, 
blocking the release of excitatory neurotransmitters (Fig. 4). This block is obtained inducing 
changes (inhibition) of calcium channels activity in pre-synaptic neurones and alterations of 
hyperpolarization (activation of potassium channels) in postsynaptic neurones (terenius). 
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The binding sites of the various opioid receptors are sufficiently flexible to accommodate 
structurally different ligands and to allow selectivity in the activation. (table 3). 
 
Fig. 3. Opioid Receptors structure 
 
Fig. 4. Opioid Receptor signalling (Modified from ref. 49) 
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Most of the common opioids, such as morphine, codeine and fentanyl, are agonists of opioid 
receptors, and act by stimulating them with different intensity and efficacy. 
Opioid receptor partial agonists, such as buprenorphine, on the contrary, bind with high 
affinity, but low efficacy at the mu receptor (partial effect). These agents can be used as 
analgesics, but have a ceiling to their analgesic effect, and increasing the dose beyond a 
certain threshold will not result in a corresponding increase in efficacy, but only in greater 
side effects (49). 
Opioid receptor Agonists-Antagonists, such as pentazocine, nalbuphine, and butorphanol, 
have poor mu opioid receptor efficacy, acting as functional antagonist, and kappa agonistic 
properties, causing undesired dysesthesias. As the partial agonist, they have a partial or a 
complete ceiling to their analgesic effect. (49). 
The opioid receptor antagonists, naloxone and naltrexone, are competitive antagonists at the 
mu, kappa, and delta receptors, in particular, with a high affinity for the mu receptor, but 
lacking any mu receptor efficacy, hence they do not activate the opioid cascade. (49). 
2.4 Biological consequences of long-term intrathecal administration of opioids 
In the last years data have been accumulated on the biological effects of systemic 
administration of morphine (50-52). Less is known about the effects of spinaly administered 
opioids on various body systems which are not purely nociceptive. 
Biological systems are characterized by an accurate mechanism of auto-control. Indeed, we 
call homeostasis the tendency to uniformity or stability in the normal body states (internal 
environment or fluid matrix) of the organism. This tendency aims at maintaining the 
organism under optimal physiological condition (53). Whenever a biological system is 
altered, a congruent cascade of physiological response is activated to eliminate the 
perturbation factor and to circumscribe the effects of the biological answer to that 
perturbation. Examples for such behaviour are the immune and the endocrine system. The 
homeostatic regulation of these systems normally occurs through a feedback mechanism, 
driven by their own products. Moreover, it is known that many regulatory molecules may 
exert their effect, directly or indirectly, on more than one system. Cytokines, the principle 
mediators of the immune system, are a known example for such regulatory molecules. 
Homeostasis fails when the feedback mechanism is overwhelmed by the perturbation factor 
or when a positive feedback occurs and the biological answer is perpetuated, not being 
counterbalanced by a suitable reaction in the opposite sense. 
A growing body of evidence suggests that exogenous and endogenous opioids influence 
both the endocrine and the immune systems and that they share many properties of the 
cytokines (54). This concept is of an extreme clinical relevance. Indeed, as opioids are shown 
to have a regulation role of the above mentioned systems, a careful insight is needed to 
understand the biological impact of their utilization in long term pain treatments. 
2.5 Opioid Immunomodulation 
Exogenous opioids are known to mediate immunosuppression, while endogenous opiates 
enhance immune function (54). In vitro, the augmentation of natural killer (NK) cell activity 
by endogenous opiates is antagonized by naloxone (55). These findings are consistent with 
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the notion that opioid receptors are expressed by immunocytes. Administration of opioids 
has been associated with increased vulnerability to infections in humans and with reduced 
survival in animals bearing tumours. In fact, administration of opioids inhibits NK cell 
activity, immune response, cytokine expression and phagocytosis. 
Both central and peripheral mechanisms are implied in the exogenous opioids 
immunosuppression. Central mechanism may involve both the hypothalamic-pituitary-
adrenal pathway and the autonomic nervous system. It is believed that the latter is implied 
during acute administration of morphine whereas the former during chronic administration. 
It is noteworthy that in the periphery, cytokines may induce endogenous opioids secretion 
from immunocytes and influence both analgesia and inflammation. On the other hand, 
exogenous opioids may induce the secretion and the expression of inflammatory cytokines 
in peripheral immunocytes. Thus opioids may be considered as an important inflammation 
and immune regulatory molecules. 
Modulation of immune response by central opioid receptors has been described (56-60). It has 
been reported that such modulation involves the delayed-type hypersensitivity reactions and 
humoral immune responses. Moreover, it appears that central immune modulation is 
influenced by the type of the activated opioid receptor, as well as by the source and nature of 
the opioid agonist. Indeed, different endogenous opioid effect differentially humoral and cell 
mediated immune responses by differentially activating brain μ, ǅ and κ opioid receptors. 
Permissive central immunomodulatory action of endogenous opioids seems to be mediated by 
the μ and ǅ receptors while suppression by the κ receptor (54). Further, acute administration of 
morphine seems to alter immune response through the activation of the sympathetic system 
while long term morphine administration decreases lymphocyte proliferation and NK cell 
activity by the modulation of the hypothalamic-pituitary-adrenal axis (61). Moreover there is a 
direct correlation with the way of administration and that the intraspinally way cause an 
important immunosupressive effect on NK and lymphokine activated killer (LAK) cells 
cytotoxic activity via a second messenger probably prolactin (PRL) mediated (15) and an 
interfrence on u-receptor expression (62). 
So, opiates widely influence the immune system and may be considered as cytokines. Opioid 
receptors that mediate immunomodulation are located in the central nervous system, 
peripheral sensory neurons, and immunocytes. Activation of these receptors exerts direct or 
indirect immunomodulation in a complex fashion. Exogenous opioids tend to suppress cell-
mediated immune function especially when administered systemically. Hence, the route of 
exogenous opioid administration may play an important role in preventing 
immunosuppression. Indeed, theoretically, the intrathecal route may avoid central and 
peripheral opioid receptors and hence reduce the likelihood of opioid immunosuppression (54). 
2.6 Opioid and the endocrine system 
Opioids are known to interfere with the neuroendocrine function (63). Animals and humans 
studies have explored both the acute and the chronic neuroendocrine effects of opiates and 
different opioid peptides. Acute administration of opioids in humans increases the secretion of 
PRL, growth hormone (GH), thyroid-stimulating hormone (TSH), and adrenocorticotropic 
hormone (ACTH) while it inhibits the release of luteinizing hormone (LH) (64, 52). It has been 
argued that the inhibition of LH release is mediated through central inhibition of 
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hypothalamic GnRH secretion (65). Opioids influence on endocrine pathways and products is 
mediated by endogenous opioid legands. It has been reported that PRL and TSH secretion is 
probably modulated by the ǆ and μ receptors, respectively while ACTH secretion by ǅ or κ 
receptors; ǆ receptors are thought to be involved in the inhibitory control of LH (66, 67). The 
receptors involved in GH modulation have not been established yet. 
Endocrine response to chronic administration of opioids differs from that of acute 
administration. In fact, the increased secretion of PRL, seen in the acute setting is increased 
only by systemic administration and not by intraspinally administration. No change in the 
TSH and β-endorphin secretion has been reported (62). Exogenous opioids are known to 
exert an inhibitory effect on the concomitant release of β-endorphin and ACTH through a 
feedback mechanism. Such mechanism may explain the suppression of ACTH release in 
long term opioid administration (68). 
It has been reported recently that long term intrathecal opioid therapy induces 
hypogonadotropic hypogonadism (69) and that altered sexual function and low testosterone 
levels may be observed in individuals addicted to opioids or on methadone maintenance or 
in males with chronic non-cancer pain treated with intrathecal opioids (70, 71). 
In conclusion, chronic opioid administration influence multiple endocrine functions. Data on 
this issue are scantly regarded in the literature. Yet, the advent of endocrine effects of opioid 
therapy cannot be ignored as it has no doubt an extraordinary clinical relevance especially in 
young adults. Particular attention should be paid to wether the administration route of chronic 
opioid therapy has any influence on the endocrine response to long term opioid therapy. 
2.7 Indications and contraindication for IT therapy 
Intrathecal analgesia is a key pain therapy for patients who have failed other treatment 
routes as well as patients with adequate analgesia on high dose enteral or parenteral therapy 
but with unacceptable side effects. The current body of literature supports the use of 
intrathecal agents for the treatment of moderate or severe pain related to cancer and non-
cancer origins (72).  
It emerges, in particular, that the evidence for opioid intrathecal infusion efficacy was strong 
for short-term improvement in pain of malignancy or neuropathic pain (73). The evidence 
was moderate for long-term management of persistent pain, and reasonably strong for long-
term therapy of cancer pain. The evidence supporting long-term efficacy in persistent non-
cancer pain is however less convincing (73). 
As concerning more specifically the type of pain responding to IT morphine, it is effective 
for long-term treatment of neuropathic-nociceptive, peripheral neuropathic, deafferentation 
and nociceptive pain, resulting in significant improvement over baseline levels of visual 
analog scale pain (74). Other types of pain indicated for IDDS are failed back syndrome, 
axial spinal pain, complex regional pain syndrome, widespread pain, central pain, pain non-
responding to spinal cord stimulation (SCS), arachnoiditis, central neuropathic pain (post-
stroke, spinal cord). 
Intrathecal delivery systems (IDDSs) have also short-term clinical success in pain control, 
reduce significantly common drug toxicities, and improved survival in patients with 
refractory cancer pain (75). 
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The most important authors use and results on cancer and non cancer pain are reported in 
tables 4 and 5. 
 
Table 4. Intraspinal therapy: cancer pain 
 
Table 5. Intraspinal therapy :non-cancer pain 
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The implantation of IDDS is contraindicated (surgical contraindication) in every case of 
serious cardiovascular disease, coagulation disorders, anatomical abnormalities of the spine 
and/or bone infections, in place, CSF fistulas, abnormal CSF flow, anatomical 
malformations that impede the creation of a pocket for the pump accommodation. There are 
also opioid-related contraindications, including severe respiratory failure, intolerance to 
opiates, and opioid non-responsiveness as emerged from pre-implant spinal test. 
2.8 IT devices 
Intrathecal drug administration is usually provided by a programmable Infusion Pump, a 
small machine implanted in patients’ bodies (fig. 5) which allow IT infusion of drug stored 
in their reservoir (fig. 6). Their electronic and mechanic devices work with precision and 
reliability and allow liquid infusion for some hours to few months’ periods, during that time 
a strict control of the amount infused is essential. In this way pump therapy allows drug 
administration only when it’s required, keeping drug amount between prescribed limits. 
The benefits of an infusion pump are summarised in table (6).  
 
Fig. 5. Spinal Space and localization of the Infusion pump 
 
Fig. 6. Characteristics of infusion pump 
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Table 6. Benefits of infusion pump 
All systems of infusion are constituted by two implanted components: a pump and a 
catheter. The pump has a central reservoir where it stores and delivers the drug daily basis 
the amount prescribed. This reservoir has a filling port, which is used for the refilling. The 
pump is provided with an antibacterial filter and of a point of secondary access, which 
allows a direct access to the catheter and consequently to the space where this ends, that the 
doctor may use to administer drugs or solutions directly in the catheter, skipping the pump. 
The catheter is a flexible tube connected to a port of the pump, and brings the drug to the 
area of the body designated. 
A surgical operation is required for the implantation of a programmable pump and a 
catheter in the body. The potential risks correlated with the implantation are: infection to the 
point of implantation; displacement, blockage or entanglement of the catheter; run out of the 
pump internal battery; breakage of device components, requiring a pump replacement. 
The core of the infusion system, which is commonly called pump, is a metal disc with a 
diameter of 7 cm and a thickness of 3 cm (weight 180 gr.), which is made entirely of titanium 
and silicon (highly bio-compatible materials). The pump is provided with an antibacterial 
filter and of a point of secondary access, which allows a direct access to the catheter (a small 
tube a few millimeters in diameter and 20 to 30 cm long silicone). Each type of pump has its 
specific catheter, which are sold together. 
The pump includes 3 sealed chambers: one containing the propellant of the reservoir, the 
second a hybrid electronic module and the battery and the third contains a peristaltic pump 
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and reservoir for the drug (fig. 6). The peristaltic pump pushes the drug through an 
elastomeric connector, from the reservoir to a catheter, and then up to the site of 
administration. 
The electronic circuits control the pump function, while the valve of the prevents the further 
introduction of fluid into the reservoir once it reaches its full capacity. This type of pump is 
reliable and more secure compared to other systems with gas propellants, as it is not 
affected by variations in temperature or pressure, ensuring an accurate control of the 
amount to be infused. 
The reservoir for the drug has a capacity of 18-20 ml (Isomed and Syncromed) or 40 ml 
(Archimedes), and is made of titanium. The electronic circuit is composed of: a lithium 
thionyl chloride battery, with 44 months of autonomy to a continuous flow of 0.5-1 ml / day 
(Isomed, Archimedes respectively) or less in case of the syncromed model; an antenna 
allowing the contact with the operator. 
The electronic module is the system memory, where are stored all the data such as the drug 
concentration, residual quantity, unit of measurement and data relative to the infusion 
programme (amount and timing). 
It is possible to perform rest periods, filling the pump with saline solution thus allowing for 
a continuous washing of the catheter, as a prevention of the risk of occlusion resulting from 
the return of blood, in the case the catheter remains empty for a long time. 
Refilling operations are limited to the puncture (fig. 7), through the skin with a Huber 
needle, of the self-sealing septum, which can be localized with palpation by the physician. 
 
Fig. 7. Refilling procedure 
A programmer interacts with the pump by establishing a contact in radiofrequency (fig. 8) 
thanks to which you can get a report of the programming parameters and of the prescription 
of medication (quantity and time of infusion). There are different models of pump, but can 
be divided into 2 types: fixed flux and electronic pumps, which are fully programmable via 
an external computer with telemetry head, they are battery powered and can last from 5 to 7 
years of life, the most popular model is the Synchromed (fig. 9). 
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Fig. 8. Pump programer 
 
Fig. 9. Programmable infusion pump 
The programmable parameters for Syncromed type of pumps are the following: date and 
time of refilling; identification of the patient, name and concentration of the drug; mode of 
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infusion, dosage of the drug and rate of administration; volume of the reservoir and low 
alarm setting reservoir; low battery alarm control (acoustic). 
The Syncromed (Medtronic Italia, S.p.A., Rome, Italy) pumps are, moreover, supplied of 
acoustic alarm systems, which signal: drug in exhaustion (falls below the level of reserves); 
battery in exhaustion; memory alterations programming. 
Isomed (Medtronic Italia, S.p.A., Rome, Italy) and Archimedes (Anschütz, Kiel, Germany) 
models are at constant flux (fig. 10), and hence at the refilling the daily concentration is 
attained modulating the refilling solution concentration, taking into account the daily flux 
(0,5 or 1 ml/day).  
 
Fig. 10. Fixed flux infusion pump 
Fixed flow pumps have a longer life by virtue of the absence of batteries, but are less precise 
than in the selection of the dose and can not afford the infusion of doses differentiated 
throughout the day, but for the change of dosage is required the emptying of the pump and 
filling with a new solution, to the dosage selected. 
3. Patient selection 
Careful patient selection is a fundamental factor for the positive outcome to the treatment. 
Intrathecal administration should be considered in patients who are unresponsive to 
treatment with oral opiates due to ineffective therapy or to intolerable side effects, who have 
good circulation of the cerebrospinal fluid and who possess a life expectancy of at least three 
months as diagnosed by the pain specialist and the oncologist. 
Before beginning treatment, patients must pass a screening test which can be epidural or 
intrathecal. The intrathecal test is performed with single intrathecal injections of drug at L2-
3 via a 27 Gauge Whitacre spinal needle (Becton Dickinson Caribe LTD. Juncos, PR), while 
patients is in prone position with a pillow under the chest, to keep the spine stretched. 
Agents used for this trial included either morphine 0,1 mg and isobaric-bupivacaine (0,5%) 
0,125 mg, or saline solution (2ml) for the placebo test (3). This trial for efficacy and safety 
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lasts usually 7 days. Placebo or morphine/bupivacaine IT injections are administered to 
patients on days 1, 3 and 7 of the trial. Patients are considered to be positive responders to 
IT analgesia if they have pain relief > 70% after administration of morphine and 
bupivacaine, and <30% after injection of the placebo. The dosage of morphine/bupivacaine 
that provided relief of pain during the trial is the initial dose used after implantation.  
If a patient does not respond optimally to the morphine, another test is carried out using a 
different opioid (e.g. hydromorphone, fentanyl, sufentanil); ziconotide or, depending on the 
type of pain, a combination of opiates + local anaesthetic (e.g. bupivacaine) or clonidine. 
Patients responding positively to the test, the are programmed for implantation of the 
infusion system. Firstly a temporary implant is used, which includes a catheter implanted 
that is connected to an external pump CADD (Smiths-Medical Italia, S.r.l., Latina, Italy), 
which is programmable.  
IT drug titration is performed as follows: the initial morphine dose is 0.1 mg/day, in order 
to limit side effects, during the post-operative period, if the pain is not adequately controlled 
(Visual analogue scale, VAS 0-10 reduction <3 points), the dosage is increased of 20% after 
3-5 days. Then increments of 10% to 20% are used until pain is attenuated or intolerable side 
effects appear. When morphine dose is 0.5mg/day, then 0.5mg/day of bupivacaine is added 
to morphine infusion, if pain is still not controlled. The bupivacaine dose is then increased of 
0.25mgs/day until a pain reduction =3 points in VAS (fig. 11). After two increases of 
bupivacaine dosage, if the VAS reduction is still < 3 points, then the dosage of morphine is 
increased (max dosage 1.0mg/day) (76). 
 
Fig. 11. VAS scale 
When a optimal response is obtained (usually after 1-2 months), the permanent pump is 
implanted: after a precise preventive antibiotic therapy, and local anesthesia, the catheter, 
previously implanted, is connected to a pump that is inserted into a pocket under the skin, 
generally in the abdomen. The totally implanted pump is not visible outside and allows the 
subject to be free to move and make a normal life. 
Management of patients throughout the various stages of the treatment should be based on 
a multidisciplinary approach involving psychologists, nurses, physiotherapists, social 
workers and spiritual advisors. 
The selection criteria which characterize patients with cancer pain or non-malignant pain are 
similar. However, patients with non-malignant pain require a more comprehensive psycho-
social assessment.  
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Regarding the cost-effectiveness of intrathecal therapy for the treatment of pain, even 
though initial costs, associated with the surgical implant of an intrathecal pump, appear to 
be substantial; moreover the maintenance costs of intrathecal administration are 
significantly lower over time compared to other methods of delivery. In this way the overall 
cost of the therapy is reduced in the long term (21). Cost analysis of alternative methods 
(including oral) for the administration of opiates indicates that intrathecal treatment is more 
cost-effective in patients who require long-term management of cancer pain (≥ 3-6 months) 
or non-malignant pain (≥ 11-22 months). 
4. Risk associated with intrathecal administration 
Intrathecal administration of analgesic agents have some risks: specific drug-related side-
effects, medical complications (surgery), and technical complications related to the infusion 
device (77) (table 7, 8). Extremely dangerous are the complications related to pump delivery 
malfunctions, which may cause high dosage infusion or acute withdrawal (table 7), resulting 
in life-threatening side effects, such as coma or death. 
 
Table 7. Complications of infusion pump  
Withdrawal syndrome can also be observed if refilling is not performed inside the correct 
range of time, for this reason it is extremely important to refill the pump at least 2-3 days 
before the emptying of the reservoir. In any case of withdrawal a substitutive oral opioid 
therapy must be promptly started, while technical problems are solved. 
Moreover, regarding cancer pain, there is a hesitancy to use invasive techniques by 
palliative care physicians in cancer patients at the end of life because their patients are often 
weak and suffering from frequent changes in painful pathology. In addition, there also is a 
low level of awareness of the procedures involved and a lack of professionals who are 
expert in the field. 
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Table 8. Drug-related complications of infusion pump 
Anyway it is believed that the benefits of this method (table 6) could greatly outweigh the 
possible risks of implanting these devices and that prevention, early identification, and 
rapid management of the adverse effects, could allow for an optimal clinical outcome for the 
patients (77). 
Intraoperative complications are extremely rare, and may be related to perforation of the 
dura mater that, given the calibre of the needle, can cause clinically significant CSF loss 
during the perioperative period, and require treatment with blood-patch and normal 
therapies indicated in such situations. Another complication is the bleeding into the 
epidural space, which can occur only if the patient has severe bleeding disorder, which is 
why blood tests are performed pre-operatively, to exclude patients with such problems. As 
concerning post operative complications, they are summarised in table 7. 
Sometimes experts in this spinal procedure dedicate insufficient attention to the interference 
between drugs (opioids) given and its effects on biological functions. Today, failure to 
understand the side-effects of intrathecal therapy by a implanting physician might be 
considered negligence, because it has been known for a long time that the use of opioids, for 
both acute and chronic pain, modifies the release of hypopituitary hormones and the 
activity of immune cells (62, 50). We believe that this spinal procedure should include 
clinical risk management and monitoring of hormonal function in all individuals (52). 
4.1 Drug-related side-effects 
The side effects associated with intrathecal administration of opiates or other analgesics are 
similar to those produced by systemic administration, but the delivery of extremely low 
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doses means that the most important side effects (table 9), such as respiratory depression, 
are avoided or lessened (78). 
 
Table 9. Opioid related adverse events 
The most serious risk associated with intrathecal morphine was the development of 
respiratory depression, even if it is extremely rare, appearing in only 1% of cases. It can arise 
in the 3 to 16 hours following infusion. For this reason, patients need to be carefully 
monitored, above all in the 24 hours following infusion or a dose increase. Hyperalgesia, 
myoclonus, urinary retention, nausea, vomiting and itching are other side effects associated 
with the use of spinal opiates, above all in patients which require higher dosages. 
Slow titration of the dosage, suitable prophylactic co-treatment and careful patient screening 
mean many of the side effects can be avoided. Management of the side effects associated 
with intrathecal administration of opiates involves reducing opiate doses, administering 
adjuvant drugs or, in serious cases, an opiate receptor antagonist. The side effects can be 
reduced by changing to another opiate (e.g. hydromorphone), or by combining bupivacaine 
or clonidine to a smaller dose of morphine. 
There are dose-related effects to the use of bupivacaine. Side-effects such as paresthesia, 
motorsensory block, arterial hypotension, and urinary retention are associated with the 
anesthetic effects of bupivacaine at spinal levels, usually linked to daily doses above 45 mg 
/ day (79). The delivery of lower doses of bupivacaine means that these side-effects can be 
avoided or lessened.  
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Slow titration of a given dose, suitable prophylactic pre-treatment and careful patient 
screening may mitigate many of these side-effects. Management of the side-effects associated 
with intrathecal administration of opioids involves reducing opioid-doses, administering 
adjuvant medications or, in serious cases, an opioid-receptor antagonist. The side-effects also 
can be reduced by changing to another opioid as in opioid rotation (e.g., hydromorphone), or 
by combining bupivacaine or clonidine to a smaller dose of the opioid infused. 
4.2 Opioid: Addiction and tolerance 
One of the worst risks associated to the opioid use is the rise of tolerance and addiction. 
Drug addiction is a constant psychological and physical craving for legal or illegal 
substances, even in the face of adverse consequences, according to the National Institute on 
Drug Abuse. Drug addiction is a disease, because drug abuse causes changes in brain 
chemistry that make it difficult to function without the substance of choice; however, like 
diabetes and heart disease, it can be managed with proper intervention. Biology, genetic 
development and living environment may all play a role in why some people become 
addicts and other users do not. 
The term “addiction” is often applied to two phenomena, one psychological, the other 
physical, which must be clearly distinguished from each other (80, 81). On one hand there is 
the irresistible urge to take the drug, on the other the sudden deprivation syndrome, both 
depending by the drug intake in the organism. The neuro-anatomical substrates of these two 
phenomena appear distinct. Bulbar and mesencephalic structures, particularly the Locus 
Coeruleus, the Raphe Nucleus and Periaqueductal gray matter, are involved in the event of the 
withdrawal syndrome. Limbic territories (Ventral Nidbrain, Ventral Striatum, Hippocampus, 
Amygdala, etc) are involved mainly in the persistent desire for opioids and in the mechanism 
of addiction that they generate. The mesolimbic dopaminergic system plays a central role, as it 
is involved in both the euphoric effects of opioids, both in the modulation of neuronal circuits, 
which are directly responsible of the withdrawal symptom (82). 
Repeated administration of opioids can result in the development of tolerance, which can be 
defined as the rightward shift of the dose response curve for a substance. The associative 
tolerance is related to conditioning, while the so-called pharmacological tolerance is due to 
the mechanism of action of the drug. The pharmacological tolerance may be due to 
constitutional factors, changes in pharmacokinetic or, more frequently, due to decreased 
pharmacodynamic effects of analgesic related to some process of neural adaptation. 
These processes are characterized by great variability intra- and interpatient. Tolerance to 
different effects of opioids develops at different speeds and can occur quickly after acute 
administration or develop more gradually as the recurrence of the hiring (83, 84). 
Development of tolerance can be maintained during long-term administration or appear 
and progress quickly in the first phase of treatment.  
Opioids exert their actions via membrane receptors which are coupled to their effectors by G 
protein. Scientist tried to find out whether these alterations are involved in the different 
elements of tolerance and dependence. Probably changes in the number and/or affinity of 
opioid receptors for their ligands are mechanisms that are not involved. In fact, when these 
changes are eventually found, tolerance and dependence have already developed; therefore, 
alterations of receptors would rather be the consequences and not the cause of tolerance and 
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dependence. On the other hand, a functional coupling between opioid receptors and their 
effectors is probably one of the mechanisms involved in the development of tolerance to 
morphinomimetics, despite the interaction mechanism is still not clearly established (83). 
Recently an imbalance between the excitatory and inhibitory effects of opioids was 
suggested. In fact, in addition to classical receptors responsible for the actions of opioids, 
whose stimulation causes inhibitory effects that result in a hyperpolarization of neurons and 
a reduction of the release of neurotransmitters, there are opioid receptors whose stimulation 
has the opposite excitatory effect. Agonists have a much greater affinity for these excitatory 
receptors than for the inhibitory ones (85). In other words, the effect of the stimulation on 
opioid receptors, including their analgesic action (86), it would be the result of: the exciter 
action connected to the involvement of higher-affinity receptors for the agonists; and of the 
inhibitory action due to lower-affinity receptors stimulation (87). Chronic treatment with 
opioids results in a reduction of its inhibitory influence and a hypersensitivity to its action 
exciter (88,89). It is believed that these alterations may be involved in the development of 
tolerance to the inhibitory effects of opioids and in the manifestations of withdrawal 
syndrome. 
The morphinomimetics influence the activity of neurons that have opioid receptors and a 
number of neurons networks are involved in a given pharmacological effect of these substances. 
Many neuronal central regions and almost all neurotransmitters, such as dopamine, 
norepinephrine, serotonin, acetylcholine and GABA (90), are implicated in the onset or 
expression of different manifestations of tolerance and/or morphine addiction. Recently the 
role of excitatory amino acids (EAA) was emphasised, in fact, blocking some EAA receptors 
(NMDA) inhibits the development of tolerance to the analgesic effects of morphine (80). 
Some of the target neurons of morphinomimetics could be part of a homeostatic system that 
tends to reduce the action of opioids. Thus opioids would activate neurons which would 
release neuropeptides, that act as antagonists of endogenous opioids. The hyperactivity of 
neurons to cholecystokinin-8 (CCK-8) and to neuropeptide FF (NPFF), induced by prolonged 
administration of morphine, is partly the cause of drug tolerance and addiction (91). 
The different hypotheses are not mutually exclusive; it is likely that these different 
mechanisms contribute to the appearance of tolerance and dependence in different ways 
and degrees. Tolerance develops as a result of spinal administration of opioids, although it 
seems to grow more slowly and in a reduced way than the use of systemic opioids (92). 
5. Guidelines to threat patiens intrathecally 
Management of patients throughout the various stages of the diagnosis and treatment of 
pain should be based on multidisciplinary expertise. Careful patient selection is the one 
fundamental factor accounting for positive outcomes to treatment. 
These are the suggested criteria for patients receiving intrathecal therapy: 
 Intrathecal administration should be reserved for patients who are unresponsive or 
poorly responsive to treatment with oral /transdermal opioids, either because of the 
development of tolerance, in spite of sequential drug trialing, or because of the 
development of dose-specific side-effects. 
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 The selection criteria for patients with cancer pain or noncancer pain are similar. 
However, patients with noncancer pain, because of their life expectancy, should require 
a more comprehensive sychosocial assessment.  
 A psychosocial evaluation should explore: 
1. patients’ expectations of their therapy, 
2. analyze the quality of the patient’s pain and the meaning of the pain to the patient, 
3. the presence of psychologic disease that might prevent adequate outcomes to the 
therapy, and 
4. barriers to patient and family compliance to the use of the pump system. 
 No pathology on cerebrospinal fluid found. 
 Informed consent to the procedure. 
Step no. 1 
A temporary trial of spinal opioid therapy should be performed to assess the potential benefits 
of this approach before implantation. In order to be considered an ideal candidate for 
intrathecal administration, a patient must demonstrate a reduction in pain of at least 50% with 
the observable absence of intolerable side-effects from the agent tested. Morphine should be the 
first agent trialed because more is known about morphine than any other agent. If a patient 
does not respond optimally to morphine, an another agent should be trialed such as 
hydromorphone, fentanyl, sufentanil, or, depending on the type of pain, as in neuropahtic pain, 
a combination of opioids and local anesthetic (e.g., bupivacaine). Many differing methods for 
this trial have been reported, such as the continuous epidural or intrathecal infusion of agents or 
single shot injections of these agents, either epidural or intrathecal (93, 94). 
Step no. 2 
After a successful trial and once the pump has been implanted, the initial daily dose of 
morphine or agent found to be the best at trial should be that dose that gave the most 
efficacious response at the time of trial. In an effort to limit side-effects during the initial 
postoperative therapy period, an intrathecal morphine dose, that is 20% lower than the 
screening test dose, should be used. The initial dose should be increased, if necessary, by 
20% every 3–5 days until the dose used at trial is reached. After that dose has been reached, 
increases in dose should be by increments of no more that 10% to 20% until pain control is 
reached or until intolerable side-effects appear. 
Monitoring 
Patients with implanted drug delivery systems must be monitored at regular intervals of 
time. Monitoring for efficacy and side-effects, especially those due to perturbations of the 
endocrine system, is good medicine and standard of care. 
Anyway a clear standard for the correlation of a specific combination of drugs to the 
treatment of a specific type of pain is still lacking. An effective dose of opioids is variable 
and individual to the needs of each and every patient; however, the effective dose of any 
one opioid often reaches high levels for various reasons including syndromespecific opioid 
resistance, receptor phenotype-determined resistance, and/or tolerance to the opioid 
delivered. Appropriate patients are selected for Intrathecal Drug Delivery System using IT / 
epidural trials either by single shot injection or titration through an implanted catheter until 
effective dosage is reached (33). 
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6. IT in geriatric population 
The IT administration of low-dose agents for the attainment of satisfactory pain control is 
particularly important for the geriatric population. Nowadays, the number of elderly people 
and the average age of the population are increasing. The elderly often suffer from age-
related diseases such as vascular cardiopathies, cerebrovascular diseases, osteoporosis, and 
arthrosis, which are, in-ofthemselves, themselves allergenic (95) and from pneumonias, 
diabetes, peripheral arterial diseases, and fractures, which generate further pain (96). These 
diseases result in serious disabilities and limitation of patients’ physical, cognitive, and 
social activities, resulting in loss of the autonomy and worsening of their quality of life. For 
this reason, it is of primary importance to find an efficient analgesic therapy for the elderly 
that avoids pharmacologic interactions with other medications used by patients for the 
treatment of their comorbid diseases that result in unwanted effects and adverse events. It is 
also well established that the elderly (older than 64 years) need lower doses of drugs to 
achieve the same level of efficacy that younger patients need. The aging process, indeed, 
involves a series of metabolic modifications that result in important alterations of the 
pharmacokinetics and dynamics of a drug (97). In particular, the reduction of body water 
level results in a reduced distribution of hydrophilic drugs, such as morphine. Similarly, the 
agerelated reduction of plasma proteins causes an increase in the concentration of active 
drug and, hence, a reduction in drug dosage needed. Moreover, the decrease of renal and 
hepatic output requires an adjustment of drug dosages given to the elderly (98, 99).  
7. Future work 
Intrathecal pump implantation has its advantages and its advantages; the main concern is if 
the elimination of systemic side-effects justifies an invasive procedure with its own potential 
serious complications. The costs of the device is high, however, it is cost-effective in the long 
term in patients responding to this treatment (100). 
From the literature, actually, there is no solid outcome evidence that supports intrathecal 
therapy use, indeed, randomized studies are still scarce, and in several studies the number 
of patients is low.  
Despite the fact that opioids and morphine in particular are the most used intrathecal drug, 
ziconotide is increasingly used for intrathecal therapy. It has also been recently indicated as 
first line IT drug by the Polyanalgesic Consensus Conference (45), thanks to its property and 
efficacy (101-104), and it is extremely useful also for patients intolerant or refractory to the 
common IT drugs (such as morphine).  
Our recent work shows that ziconotide has good levels of efficacy and long-term safety, 
which can be attained at stable doses with a constant pain relief, suggesting the absence of 
tolerance effects (104). This suggests, moreover, that, once the early side effects are 
overcome, the responders are not exposed to long-term risks. 
We believe that this drug has a great potential for future IT therapy, in order to reduce 
common long-term opioid related adverse events: immunomodulation, influence on the 
endocrine system and tolerance. 
IT therapy, moreover is useful also for the treatment of spasticity: baclofen is widely applied 
for this purpose (105-108), alone or in association with ziconotide, or local anesthetics, in 
cases of spasticity associated with pain (73, 108). 
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8. Conclusion 
Intrathecal administration of drugs by qualified personnel significantly enhances pain relief 
and improves the quality of life in patients who fail conservative therapies with oral or 
transdermal delivery of analgesics, while reducing the risk of adverse effects and 
complications. According to indications suggested by the International Consensus 
Conference (17), that took place in Belgium in 1998, the fundamental prerequisite for the 
correct application of intrathecal therapy with opioids is appropriate professional training 
regarding: catheter and pump implant procedures; knowledge of the anatomy, physiology, 
and neuropharmacology of the neuromodulatory centers of the spinal cord and the brain; 
knowledge of systemic complications; a multidisciplinary approach to care. 
However, because the literature is bereft of good clinical science that pertains to intrathecal 
therapy and is full of anecdotal material, we believe that long-term prospective and 
randomized studies are necessary to fully evaluate the safety and efficacy of the intrathecal 
administration of opioids and nonopioids alike for pain relief. It is important that these 
prospective, randomized, controlled trials identify not only the efficacy of intrathecal to 
provide pain management, but also the biological impact that the route of administration of 
analgesics (systemic vs. intrathecal) has on the general health and well-being of the patient.  
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